Early sympathetic activation in the initial clinical stages of chronic renal failure

Hypertension

Volumn 57, Issue 4, 2011, Pages 846-851

  Grassi, Guido ^a,e   Quarti Trevano, Fosca ^a   Seravalle, Gino ^b   Arenare, Francesca ^a   Volpe, Marco ^a,c   Furiani, Silvia ^d   Delloro, Raffaella ^a   Mancia, Giuseppe ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

^d Ospedale Bassini   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

Author keywords

chronic renal failure; microneurography; sympathetic nervous system

Indexed keywords

NORADRENALIN;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY FAILURE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; EFFERENT NERVE; FEMALE; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; SYMPATHETIC FUNCTION; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BAROREFLEX; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NOREPINEPHRINE; SYMPATHETIC NERVOUS SYSTEM;

EID: 79953177793     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.164780     Document Type: Article

References (43)

1. McGrath BP, Ledingham JG, Benedict CR. Catecholamines in peripheral venous plasma in patients on chronic haemodialysis. Clin Sci Mol Med. 1978;55:89-96. (Pubitemid 8382449)
2. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-1918. (Pubitemid 23006966)
3. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol. 2001;12:2427-2433. (Pubitemid 33021120)
4. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974-1979. (Pubitemid 35176304)
5. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol. 2003;14:3239-3244. (Pubitemid 37509299)
6. Zilch O, Vos PF, Oey PL, Cramer MJ, Ligtenberg G, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens. 2007;25:1285-1289. (Pubitemid 46918809)
7. Ranpuria R, Hall M, Chan CT, Unruh M. Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV. Nephrol Dial Transplant. 2008;23:444-449. (Pubitemid 351767627)
8. Axelrod S, Lishner M, Oz O, Bernheim J, Ravid M. Spectral analysis of fluctuations in heart rate: an objective evaluation of autonomic nervous control in chronic renal failure. Nephron. 1987;45:202-206. (Pubitemid 17013821)
9. Di Leo R, Vita G, Messina C, Savica V. Autonomic function in elderly uremics studied by spectral analysis of heart rate. Kidney Int. 2005;67: 1521-1525. (Pubitemid 40463130)
10. Tong YQ, Hou HM. Alteration of heart rate variability parameters in nondiabetic hemodialysis patients. Am J Nephrol. 2007;27:63-69.
11. Levitan D, Massry SG, Romoff M, Campese VM. Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension: effect of clonidine. Nephron. 1984;36:24-29. (Pubitemid 14211339)
12. Ishii M, Ikeda T, Takagi M, Sugimoto T, Atarashi K, Igari T Uehara Y, Matsuaoka H, Hirata Y, Kimura K, Takeda T, Murao S. Elevated plasma catecholamines in hypertensives with primary glomerular diseases. Hypertension. 1983;5:545-551. (Pubitemid 13076694)
13. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340:1321-1328. (Pubitemid 29196594)
14. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68-72. (Pubitemid 28124694)
15. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del Bo A, Sala C, Bolla GB, Pozzi M. Mancia G. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92:3206-3211.
16. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-1359. (Pubitemid 34260428)
17. Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis. 2004;44: 84-93. (Pubitemid 38880931)
18. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
19. Devereux RB, Reicheck N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation. 1977;55:613-616.
20. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, for the American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358-367.
21. Hjemdahl P, Daleskong M, Kanan T. Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method. Life Sci. 1979;25: 131-138. (Pubitemid 9233447)
22. Grassi G, Esler MD. How to assess sympathetic activity in humans. J Hypertens. 1999;17:719-734. (Pubitemid 29322156)
23. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, Mancia G. Heart rate as marker of sympathetic activity. J Hypertens. 1998;16:1635-1639. (Pubitemid 28515490)
24. Park J, Campese VM, Nobakht N, Middlekauff HR. Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol. 2008;105:1873-1876.
25. Grassi G, Seravalle G, Arenare F, Buccianti G, Furiani S, Ilardo V, Bolla G, Mancia G. Behaviour of regional adrenergic outflow in mild-tomoderate renal failure. J Hypertens. 2009;27:562-566.
26. Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension. 1998;31:64-67. (Pubitemid 28124693)
27. Pozzi M, Grassi G, Redaelli E, Dell'Oro R, Ratti L, Redaelli A, Foglia G, Di Lelio A, Mancia G. Patterns of regional sympathetic nerve traffic in preascitic and ascitic cirrhosis. Hepatology. 2001;34:1113-1118. (Pubitemid 33096583)
28. Grassi G, Quarti-Trevano F, Seravalle G, Dell'Oro R, Dubini A, Mancia G. Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome. Metabolism. 2009;58:1446-1451.
29. Mancia G, Mark AL. Arterial baroreflexes in humans. In: Shepherd JT, Abboud FM, eds. Handbook of Physiology, Section 2: The Cardiovascular System. Bethesda, MD: American Physiological Society; 1983: 755-793.
30. Pickering TG, Gribbin B, Oliver DO. Baroreflex sensitivity in patients on long-term haemodialysis. Clin Sci. 1972;43:645-657.
31. Grassi G, Parati G, Pomidossi G, Giannattasio C, Casadei R, Bolla GB, Casati S, Graziani G, Mancia G. Effects of haemodialysis and kidney transplantation on carotid and cardiopulmonary baroreflexes in uremic patients. J Hypertens. 1987;5(suppl 5):S367-S369. (Pubitemid 18074937)
32. Hering D, Zdrojewski Z, Król E, Kara T, Kucharska W, Somers VK, Rutkowski B, Narkiewicz K. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J Hypertens. 2007;25:157-161. (Pubitemid 44885677)
33. DiBona GF. Functionally specific renal sympathetic nerve fibers: role in cardiovascular regulation. Am J Hypertens. 2001;14:163S-170S.
34. Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep. 2002;4:256-260.
35. Schlaich MP, Socratus F, hennebry S, Eikelis N, lambert EA, Straznicky N, Esler MD, Lambert GW. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20:933-939.
36. Campese VM, Kogosov E, Koss M. Renal afferents denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis. 1995;26:861-865.
37. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262:E763-E778.
38. Mallamaci F, Tripepi G, Maas R, Malatino L, Böger R, Zoccali C. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol. 2004;15:435-441. (Pubitemid 38140785)
39. Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME. The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease. Adv Ther. 2006;23:988-998. (Pubitemid 46341056)
40. Borazan A, Binici DN. Relationship between insulin resistance and inflammation markers in hemodialysis patients. Ren Fail. 2010;32:198-202.
41. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol. 2004;15:524-537. (Pubitemid 38294782)
42. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 2003;14:425-430. (Pubitemid 36150866)
43. Vonened O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21:1709-1716.